Alaunos Therapeutics (NASDAQ:TCRT) Shares Up 13.8%

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s stock price shot up 13.8% during trading on Friday . The company traded as high as $1.34 and last traded at $1.32. 50,846 shares changed hands during trading, a decline of 73% from the average session volume of 185,626 shares. The stock had previously closed at $1.16.

Alaunos Therapeutics Stock Performance

The stock’s 50-day moving average is $1.71 and its 200 day moving average is $1.57.

Institutional Investors Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. Magnolia Capital Advisors LLC bought a new stake in shares of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 432,969 shares of the company’s stock, valued at approximately $56,000. Magnolia Capital Advisors LLC owned about 0.18% of Alaunos Therapeutics as of its most recent SEC filing. 27.72% of the stock is owned by hedge funds and other institutional investors.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor engine.